title: Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.
authors.affiliation: Division of Allergy and Clinical Immunology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address: amanda.jagdis@mail.utoronto.ca.
authors.forename: Amanda
authors.initials: A
authors.lastname: Jagdis
authors.affiliation: Division of Allergy and Clinical Immunology, St Michael's Hospital, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Peter
authors.initials: P
authors.lastname: Vadas
mesh_terms: D000328:Adult; D000707:Anaphylaxis / Q000276:immunology / Q000473:pathology / Q000517:prevention & control*; D018926:Anti-Allergic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D015550:Cell Degranulation / Q000187:drug effects; D002999:Clone Cells; D005260:Female; D006801:Humans; D008407:Mast Cells / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D000069444:Omalizumab; D012008:Recurrence; D013577:Syndrome; D016896:Treatment Outcome
chemical_list: D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab